For most people, pain eventually fades away as an injury heals. But for others, the pain persists beyond the initial healing and becomes chronic, hanging on for weeks, months, or even years.
Now, we may have uncovered an answer to help explain why: subtle differences in a gene that controls how the body responds to stress.
In a recent study of more than 1,600 people injured in traffic accidents, researchers discovered that individuals with a certain variant in a stress-controlling gene, called FKBP5, were more likely to develop chronic pain than those with other variants. Continue reading →
Tapentadol prolonged release (PR) for the treatment of moderate to severe chronic pain combines 2 modes of action.
These are μ-opioid receptor agonism and noradrenaline reuptake inhibition in a single molecule that allow higher analgesic potency through modulation of different pharmacological targets within the pain-transmitting systems. Continue reading →
A rise in addiction and overdose deaths involving opioids in the United States has spurred a series of initiatives focused on reducing opioid risks, including several related to prescription of opioids in care of pain. Policy analytic scholarship provides a conceptual framework to assist in understanding this response.
Prior to 2011, a “policy monopoly” of regulators and pharmaceutical manufacturers allowed and encouraged high levels of opioid prescribing.
The authors then point out that the debate has been cornered by an “advocacy coalition” of anti-opioid fanatics: Continue reading →
Spurred by the epidemic of opioid overdoses and deaths in the United States, researchers are seeking new formulations of opioid pain relievers that will reduce the medications’ potential for misuse and overdose without compromising their analgesic effectiveness.
In one such effort, NIDA-funded researchers recently tested a combination of the prescription analgesic oxycodone and nalfurafine, which is used in Japan to treat itching associated with hemodialysis and chronic liver disease.
In the body, pain and itch are processed in very similar ways: they share a common pathway positioned in the spinal cord and also activate the same sensory brain areas.Continue reading →
Opioid-induced hyperalgesia (OIH) is a phenomenon that causes an increased pain sensitization and perception of pain to noxious stimuli secondary to opioid exposure.
While this clinical effect has been described in the surgical setting, it is unclear if OIH occurs in the nonsurgical setting.
Yet, some doctors are quick to blame any pain patient’s increased pain on this mythical phenomenon. Instead of prescribing more opioids, they use your additional pain as an excuse to cry “OIH!” and taper you down. Continue reading →